Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)

被引:71
|
作者
Xia, Guanggai [1 ]
Wang, Hongcheng [1 ]
Song, Ziliang [1 ]
Meng, Qingcai [2 ]
Huang, Xiuyan [1 ]
Huang, Xinyu [1 ]
机构
[1] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Gen Surg, 600 Yishan Rd, Shanghai 200233, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Pancreat Canc Inst, Dept Pancreat Surg, 270 Dong An Rd, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
Pancreatic cancer; Gemcitabine; Gambogic acid; RRM2; NF-KAPPA-B; CELL LUNG-CANCER; PLUS GEMCITABINE; DNA-DAMAGE; RESISTANCE; TRIAL; CHEMOTHERAPY; INHIBITION; ERLOTINIB; PATHWAYS;
D O I
10.1186/s13046-017-0579-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Pancreatic cancer is susceptible to gemcitabine resistance, and patients receive less benefit from gemcitabine chemotherapy. Previous studies report that gambogic acid possesses antineoplastic properties; however, to our knowledge, there have been no specific studies on its effects in pancreatic cancer. Therefore, the purpose of this study was to explore whether increases the sensitivity of pancreatic cancer to gemcitabine, and determine the synergistic effects of gambogic acid and gemcitabine against pancreatic cancer. Methods: The effects of gambogic acid on cell viability, the cell cycle, and apoptosis were assessed using 4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) and flow cytometry in pancreatic cancer cell lines. Protein expression was detected by western blot analysis and mRNA expression was detected using q-PCR. A xenograft tumor model of pancreatic cancer was used to investigate the synergistic effects of gambogic acid and gemcitabine. Results: Gambogic acid effectively inhibited the growth of pancreatic cancer cell lines by inducing S-phase cell cycle arrest and apoptosis. Synergistic activity of gambogic acid combined with gemcitabine was observed in PANC-1 and BxPC-3 cells based on the results of MTT, colony formation, and apoptosis assays. Western blot results demonstrated that gambogic acid sensitized gemcitabine-induced apoptosis by enhancing the expression of cleaved caspase-3, cleaved caspase-9, cleaved-PARP, and Bax, and reducing the expression of Bcl-2. In particular, gambogic acid reduced the expression of the ribonucleotide reductase subunit-M2 (RRM2) protein and mRNA, a trend that correlated with resistance to gemcitabine through inhibition of the extracellular signal-regulated kinase (ERK)/E2F1 signaling pathway. Treatment with gambogic acid and gemcitabine significantly repressed tumor growth in the xenograft pancreatic cancer model. Immunohistochemistry results demonstrated a downregulation of p-ERK, E2F1, and RRM2 in mice receiving gambogic acid treatment and combination treatment. Conclusions: These results demonstrate that gambogic acid sensitizes pancreatic cancer cells to gemcitabine in vitro and in vivo by inhibiting the activation of the ERK/E2F1/RRM2 signaling pathway. The results also indicate that gambogic acid treatment combined with gemcitabine might be a promising chemotherapy strategy for pancreatic cancer.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas
    Takao Itoi
    Atsushi Sofuni
    Noriyoshi Fukushima
    Fumihide Itokawa
    Takayoshi Tsuchiya
    Toshio Kurihara
    Fuminori Moriyasu
    Akihiko Tsuchida
    Kazuhiko Kasuya
    Journal of Gastroenterology, 2007, 42
  • [42] Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas
    Itoi, Takao
    Sofuni, Atsushi
    Fukushima, Noriyoshi
    Itokawa, Fumihide
    Tsuchiya, Takayoshi
    Kurihara, Toshio
    Moriyasu, Fuminori
    Tsuchida, Akihiko
    Kasuya, Kazuhiko
    JOURNAL OF GASTROENTEROLOGY, 2007, 42 (05) : 389 - 394
  • [43] Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma
    Han, Ping
    Lin, Zhi-Rui
    Xu, Li-Hua
    Zhong, Qian
    Zhu, Xiao-Fen
    Liang, Fa-Ya
    Cai, Qian
    Huang, Xiao-Ming
    Zeng, Mu-Sheng
    MOLECULAR MEDICINE REPORTS, 2015, 12 (01) : 401 - 409
  • [44] Transcriptional and post-transcriptional regulation of ribonucleotide reductase (RRM2) control its oncogenic role in prostate cancer progression.
    Mazzu, Ying Zhang
    Armenia, Joshua
    Chakraborty, Goutam
    Yoshikawa, Yuki
    Gerke, Travis A.
    Atiq, Mohammad Omar
    Stopsack, Konrad Hermann
    Komura, Kazumasa
    Lee, Gwo-Shu Mary
    Mucci, Lorelei A.
    Kantoff, Philip W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] RETRACTION: Retraction notice to <Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase (RRM2): a novel therapeutic strategy in pancreatic cancer (vol 136 pg 261, 2004) (Retraction of Vol 136, Pg 261, 2004)
    Duxbury, Mark S.
    Ito, Hiromichi
    Benoit, Eric
    Zinner, Michael J.
    Ashley, Stanley W.
    Whang, Edward E.
    SURGERY, 2023, 173 (04) : 1109 - 1109
  • [46] Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor
    Chow, Zeta
    Johnson, Jeremy
    Chauhan, Aman
    Jeong, Jong Cheol
    Castle, Jennifer T.
    Izumi, Tadahide
    Weiss, Heidi
    Townsend Jr, Courtney M.
    Schrader, Joerg
    Anthony, Lowell
    Yang, Eddy S.
    Evers, B. Mark
    Rychahou, Piotr
    CANCER LETTERS, 2024, 596
  • [47] Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer
    Duxbury, MS
    Ito, H
    Benoit, E
    Zinner, MJ
    Ashley, SW
    Whang, EE
    SURGERY, 2004, 136 (02) : 261 - 269
  • [48] Ribonucleotide Reductase M2 Is Not Predictive of Adjuvant Gemcitabine Treatment Benefit in Patients with Resected Pancreatic Adenocarcinoma
    Xie, H.
    Lin, J.
    Thomas, D. G.
    Jiang, W.
    Liu, X.
    MODERN PATHOLOGY, 2012, 25 : 450A - 450A
  • [49] Ribonucleotide Reductase M2 Is Not Predictive of Adjuvant Gemcitabine Treatment Benefit in Patients with Resected Pancreatic Adenocarcinoma
    Xie, H.
    Lin, J.
    Thomas, D. G.
    Jiang, W.
    Liu, X.
    LABORATORY INVESTIGATION, 2012, 92 : 450A - 450A
  • [50] Effect of Ribonucleotide Reductase Subunit 2 mRNA Expression in Pretreatment Biopsies Obtained from Pancreatic Carcinomas
    Itoi, Takao
    Sofuni, Atsushi
    Itokawa, Fumihide
    Tsuchiya, Takayoshi
    Kurihara, Toshio
    Kawai, Takashi
    Yamagishi, Tetsuya
    Moriyasu, Fuminori
    GASTROINTESTINAL ENDOSCOPY, 2006, 63 (05) : AB252 - AB252